Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior Pharmaceuticals director Juliet Thompson reported routine equity compensation and related tax withholding transactions. She received a grant of 6,518 Restricted Stock Units, each representing one share of common stock, which will vest immediately before the next annual stockholder meeting if she continues serving the company.
To satisfy tax withholding obligations from RSU vesting on May 12, 2026, 1,117 shares of common stock were withheld at a price of $38.28 per share, which is not an open-market sale. After these transactions, Thompson holds 12,973 shares directly and 5,775 shares indirectly through her spouse.
Humphreys Keith reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Keith Humphreys reported a compensation-related equity grant. He received 6,518 shares of Common Stock in the form of Restricted Stock Units, with no cash price per share shown in the filing. After this award, he directly holds 16,042 shares of the company’s stock. The RSUs vest on the day immediately before the next annual stockholder meeting following the grant date, as long as he continues serving the company until that vesting date.
Kingsley Stuart A reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Stuart A. Kingsley received an equity award of 6,518 shares of common stock in the form of restricted stock units. These RSUs were granted at $0.00 per share as compensation, not through an open-market purchase.
Each RSU represents a right to receive one share of common stock and will vest on the day immediately before the next annual stockholder meeting following the grant date, if Kingsley continues serving the company. After this award, he holds 12,100 shares of Indivior common stock directly.
Indivior Pharmaceuticals, Inc. reported that director Daniel A. Ninivaggi acquired 6,518 shares of common stock through a grant of Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of common stock at vesting.
The RSUs vest on the day immediately preceding the company’s next annual stockholder meeting, subject to his continued service. Following this equity award, Ninivaggi directly owns 27,163 shares of Indivior common stock, reflecting a routine compensation-related increase in his holdings rather than an open‑market purchase.
Ryan Barbara reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Ryan Barbara reported receiving a grant of 6,518 shares of common stock in the form of Restricted Stock Units (RSUs) at no cash cost. After this award, the director holds 12,242 common shares directly.
Each RSU represents a contingent right to receive one share of common stock and will vest on the day immediately before the next annual stockholder meeting, as long as the director continues to serve until that date. This is a compensation-related equity award rather than an open‑market purchase or sale.
Stejbach Mark reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Mark Stejbach received an equity grant of 6,518 shares of common stock in the form of restricted stock units. The RSUs vest immediately before the next annual stockholder meeting, as long as he continues serving the company, bringing his direct holdings to 27,087 shares.
Wheadon David E. reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director David E. Wheadon received a grant of 10,430 Restricted Stock Units (RSUs), each representing one share of common stock. The award is compensation rather than a cash purchase, at a stated price of $0.00 per share. Following this grant, his direct holdings total 30,780 shares. The RSUs vest the day before the next annual stockholders’ meeting after the grant date, if he continues serving the company until that vesting date.
Indivior Pharmaceuticals, Inc. ownership disclosure: Fuller & Thaler Asset Management, Inc. reports beneficial ownership of 4,529,583.47 shares of Common Stock, representing 3.72% of the class as reported in Amendment No. 1.
The filing states sole voting power of 4,351,663.47 shares and sole dispositive power of 4,529,583.47. The form is signed by the firm’s Chief Compliance Officer on 05/13/2026.
Indivior Pharmaceuticals, Inc. has entered into a $175 million accelerated share repurchase agreement (ASR) with Barclays Bank PLC as part of its previously authorized $400 million share repurchase program. Indivior made an upfront payment of $175 million and received an initial delivery of 3,717,473 common shares.
The final number of shares Indivior repurchases will depend on the volume weighted average price of its stock over the ASR term, less a discount, under the contract’s terms. Transactions under the ASR are expected to be completed by late June 2026, and Indivior does not expect this action to affect its previously issued financial guidance.
Indivior Pharmaceuticals, Inc. reported strong first-quarter 2026 results, led by its long-acting opioid use disorder treatment SUBLOCADE. Net revenue rose to $317 million from $266 million, while net income increased to $89 million from $47 million, lifting diluted EPS to $0.69.
SUBLOCADE net revenue grew 32% to $232 million, representing 73% of total net revenue, and gross margin improved to 87% as mix shifted toward higher-margin products. The company issued $500 million of 0.625% Convertible Senior Notes due 2031, repaid a $333 million term loan, and repurchased about 4 million shares for $125 million under a new $400 million buyback.
Operating cash flow turned slightly negative, mainly due to litigation settlement payments and payment timing, while restructuring tied to the Indivior Action Agenda continued, with $9 million of charges in the quarter and $40 million of related liabilities outstanding.